Information Provided By: 
Fly News Breaks for November 16, 2016
MDCO
Nov 16, 2016 | 08:05 EDT
Leerink analyst Joseph Schwartz raised his price target for The Medicines Co. to $57 from $50 following the Phase 2 ORION-1 data presentation at the American Heart Association meeting, and after the company provided an extensive walk-through of the safety findings in addition to encouraging efficacy and durability data. The analyst also raised his probability of success for inclisiran to 60% from 50%. He reiterates an Outperform rating on the shares.
News For MDCO From the Last 2 Days
There are no results for your query MDCO
